A targeted antibody-drug treatment for myeloma
Belantamab mafodotin
A targeted antibody-drug treatment for multiple myeloma that needs regular eye checks.
What is Belantamab mafodotin?
Belantamab mafodotin is a specialist targeted cancer medicine used to treat multiple myeloma, a cancer of certain bone-marrow cells. It is an antibody-drug conjugate, meaning an antibody that homes in on myeloma cells is joined to a cell-killing drug, delivering it straight to the cancer. It is given as a drip into a vein. Its most important and distinctive risk is eye problems (keratopathy), which can affect the front of the eye and your vision, so regular eye examinations are essential and treatment is managed through a special safety programme. It can also lower platelets and cause infusion reactions, and it can harm an unborn baby.
Education and reference only. This is a plain-language guide to Belantamab mafodotin — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Belantamab mafodotin is a targeted cancer medicine known as an antibody-drug conjugate. It is used to treat multiple myeloma, a cancer of plasma cells in the bone marrow. The medicine combines an antibody that seeks out a marker called BCMA on myeloma cells with a powerful cell-killing drug attached to it, so the drug is delivered mainly to the cancer cells. It is given as a drip (infusion) into a vein under specialist supervision, and because of its effects on the eyes it is used within a special monitoring and safety programme.
How it works
Myeloma cells carry a marker on their surface called BCMA. The antibody part of belantamab mafodotin attaches to this marker, then the cell takes the whole medicine inside, where the attached cell-killing drug is released and destroys the cancer cell. This targeted delivery aims to harm myeloma cells more than healthy ones. The same cell-killing part can also affect the fast-renewing cells on the surface of the eye, which is why eye problems are its most important side effect and why regular eye checks are built into treatment.
Company & origin
Originated / developed by: Specialist manufacturer.
A specialist cancer medicine used in the UK to treat multiple myeloma, given as a drip into a vein.
Practical use
How to take Belantamab mafodotin
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as a drip into a vein in hospital, so attend all your treatment appointments.
- Attend every eye examination before and during treatment, as these guide whether treatment continues, pauses or changes.
- Report any change in your vision, such as blurring, dryness or difficulty seeing, straight away.
- Use lubricating eye drops as advised and avoid contact lenses unless your team says otherwise.
- Report unusual bruising or bleeding, and use reliable contraception during treatment.
Weighing it up
Advantages & disadvantages of Belantamab mafodotin
Advantages
- A targeted treatment for multiple myeloma that delivers a cell-killing drug straight to myeloma cells.
- An option for myeloma that has come back or not responded to other treatments.
- Given under close specialist supervision with built-in eye monitoring for safety.
Disadvantages
- Commonly causes eye problems (keratopathy) and changes in vision, needing regular eye checks.
- Can lower platelets, raising the risk of bruising and bleeding, and can cause infusion reactions.
- Given by drip in hospital, within a special safety programme, and can harm an unborn baby.
Practical use
Good to know
The single most important thing to understand about belantamab mafodotin is its effect on the eyes. It can cause changes to the front surface of the eye (keratopathy) and problems with vision, such as blurring, dryness and difficulty seeing clearly. Because of this, regular eye examinations by an eye specialist are essential before and during treatment, and the medicine is given within a special safety programme; your team may delay or adjust treatment depending on what the eye checks show, and you should report any change in your vision straight away. You may be advised to avoid contact lenses and to use lubricating eye drops. It can also lower platelets, raising the risk of bruising and bleeding, and can cause reactions during the infusion. It can harm an unborn baby, so effective contraception is important during treatment.
Who should not take it / use with caution
- People who have had a serious allergic reaction to belantamab mafodotin should not have it.
- It is not suitable in pregnancy because it can harm an unborn baby; effective contraception is needed.
- It is used with caution, and with extra eye monitoring, in people with existing eye conditions, under specialist guidance.
Monitoring
- Regular eye examinations by an eye specialist before and during treatment.
- Regular blood counts, especially platelets, to watch for bleeding risk.
- Watching for infusion reactions and reviewing how the myeloma is responding.
Side effects
- Eye problems (keratopathy) and changes in vision, such as blurring, dryness and difficulty seeing clearly.
- Low platelets, leading to bruising and a greater risk of bleeding.
- Reactions during the infusion, such as fever, chills or breathlessness.
- Tiredness, nausea and changes in other blood counts.
Key interactions
- It has few well-established routine medicine interactions, but always share a full medicines list with your team.
- Other medicines that affect platelets or clotting can add to the risk of bleeding.
- Tell your team about any other cancer treatments so care can be planned safely.
Available as: A powder made up into a solution given as a drip (infusion) into a vein.
Answers
Belantamab mafodotin: frequently asked questions
What is belantamab mafodotin used for?
It is a targeted antibody-drug treatment used for multiple myeloma, delivering a cell-killing drug straight to myeloma cells by attaching to a marker called BCMA.
Why do I need regular eye checks?
It can cause changes to the front of the eye (keratopathy) and affect your vision, so regular eye examinations guide whether treatment continues, pauses or changes.
What eye symptoms should I report?
Report any blurring, dryness, difficulty seeing clearly or other change in your vision straight away, as the dose or timing may need adjusting.
How is it given?
It is given as a drip into a vein in hospital, within a special safety programme that includes regular eye monitoring.
Can I have it in pregnancy?
No. It can harm an unborn baby, so reliable contraception is important during treatment; discuss any pregnancy plans with your specialist.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.